DYAI

Dyadic to Report Second Quarter 2021 Financial Results

Dyadic Stock Shoots Higher On Technology Transfer, Licensing Pact For COVID-19 Vaccine In African Continent

DYAI Stock Increases Over 62% Intraday: Why It Happened

Dyadic Announces Technology Transfer and Licensing Agreement With South Africa's Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent

Dyadic's C1 Production Platform Utilized in ZAPI Study Published in “VACCINES” a Leading Peer-Reviewed Scientific Journal

Dyadic' Stock Jumps On COVID-19 Vaccine Development Pact In India

DYAI Stock Price: Over 12% Increase Pre-Market Explanation